Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Christoph Glanzmann"'
Autor:
Olga Unterkirhere, MD, PhD, Anna Stenger-Weisser, MD, Alexander Kaever, MD, Laura Hoeng, MD, David Jeller, MSc, Philippe Logaritsch, PhD, Christoph Glanzmann, MD, PhD, Gabriela Studer, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101270- (2023)
Purpose: We report treatment outcomes for patients who received adjuvant moderate hypofractionated whole-breast radiation therapy with simultaneous integrated boost (SIB-mhWBRT) after breast-conserving surgery. Methods and Materials: SIB-mhWBRT for p
Externí odkaz:
https://doaj.org/article/c1a73d3065c04842b0fd431f1ebb0065
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background Volumetric tumor staging has been shown as superior prognostic tool compared to the conventional TNM system in patients undergoing definitive intensity-modulated radiotherapy (IMRT) for head and neck cancer. Recently, clinical imm
Externí odkaz:
https://doaj.org/article/a16b305714a1476d828c0036eb1c9775
Autor:
Gabriela Studer, Christoph Glanzmann
Publikováno v:
Praxis. 110:733-742
Zusammenfassung. Wir geben einen Überblick über die wesentlichen Entwicklungen und Innovationen des Faches über die vergangenen Jahrzehnte, bzw. über aus dieser Entwicklung resultierende aktuelle perkutane Radiotherapie (RT)-Schemata und deren Ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76141e3dab8a104e02fceb12fcb46946
https://doi.org/10.1024/1661-8157/a003729
https://doi.org/10.1024/1661-8157/a003729
Autor:
Olga Unterkirhere, Anna Stenger-Weisser, Alexander Kaever, Laura Hoeng, David Jeller, Philippe Logaritsch, Christoph Glanzmann, Gabriella Studer
Publikováno v:
Advances in Radiation Oncology. :101270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9a443979f02de333657c5e1aa87f3e5
https://doi.org/10.1016/j.adro.2023.101270
https://doi.org/10.1016/j.adro.2023.101270
Autor:
Gabriela, Studer, Christoph, Glanzmann
Publikováno v:
Praxis. 110(13)
Radiation Oncology - Recent Status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5302dfa26a610c87b540c197f83cf0fd
https://pubmed.ncbi.nlm.nih.gov/34583545
https://pubmed.ncbi.nlm.nih.gov/34583545
Autor:
Gerhard F. Huber, Sonja Stieb, Martin Pruschy, Stephanie Tanadini-Lang, Gabriela Studer, Marius Bredell, Kaja Bertogg, Patrick Veit-Haibach, Stephan Schmid, Sandra Weber, Sabine Bender, Ulrike Held, Tamara Rordorf, Oliver Riesterer, Marta Bogowicz, Ashish Sharma, Kristian Ikenberg, Christoph Glanzmann
Background and purpose Preclinical data suggest that cetuximab should be continued after end of concurrent radiotherapy+cetuximab due to its efficacy against residual tumor cells in the irradiated tumor bed. Based on this concept the phase II add-on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c61392b0febe112c43e0bb8c8f339c71
https://www.zora.uzh.ch/id/eprint/188790/
https://www.zora.uzh.ch/id/eprint/188790/
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
BMC Cancer
BMC Cancer
Background Volumetric tumor staging has been shown as superior prognostic tool compared to the conventional TNM system in patients undergoing definitive intensity-modulated radiotherapy (IMRT) for head and neck cancer. Recently, clinical immunoscores
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9915c480a16f271f0933d7bee1df433a
http://link.springer.com/article/10.1186/s12885-017-3590-0
http://link.springer.com/article/10.1186/s12885-017-3590-0
Autor:
Gabriela Studer, Christoph Glanzmann
Publikováno v:
Deutsches Ärzteblatt international.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c55720264786db25f8b3904c119aa79
https://doi.org/10.3238/arztebl.2019.0009c
https://doi.org/10.3238/arztebl.2019.0009c
Autor:
Michelle Brown, Marius Bredell, Gerhard F. Huber, Gabriela Studer, Christoph Glanzmann, Tamara Rordorf
Publikováno v:
Strahlentherapie und Onkologie. 192:526-536
Objective Elderly patients with malignant head-and-neck tumors (HNT) often pose a therapeutic challenge. They frequently have significant comorbidities which may influence their ability to tolerate tumor-specific therapies. Our aim was to investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64cb78f28a2327e05bf956a75c9b730e
https://doi.org/10.1007/s00066-016-0986-8
https://doi.org/10.1007/s00066-016-0986-8
Autor:
Gabriela Studer, Christoph Glanzmann
Publikováno v:
Strahlentherapie Und Onkologie
Background Locoregionally advanced stage head and neck cancer (HNC) is known for unfavorable outcome with only ~ 40–50 % 3-year overall survival (OS). Clinical T4 stage includes a wide range of tumor burden. The lack of further nonsurgical subgroup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5061ab58824cd685cc8216465053a0cb
http://doc.rero.ch/record/310036/files/66_2013_Article_413.pdf
http://doc.rero.ch/record/310036/files/66_2013_Article_413.pdf